From: Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality
Authors (year) | Study population | Number | Number taking drug (percentage) | Years of follow-up | Recurrence RR (95% CI) | Breast cancer mortality RR (95% CI) | Total mortality RR (95% CI) |
---|---|---|---|---|---|---|---|
Aspirin | |||||||
Kwan et al. [10] (2007) | LACE cohort, stages I-IIIA, with linked pharmacy records | 2,292 | - | Mean 2.5 | 1.09a (0.74-1.61) | - | - |
Blair et al. [11] (2007) | Iowa Women's Health Study, post-menopausal | 591 | - | Maximum 9.5 | - | 0.53 (0.30-0.93) | 0.53 (0.36-0.79) |
Holmes et al. [12] (2010) | Nurses' Health Study, stages I-III | 4,164 | (48% of the person-time) | Maximum 30 | - | 0.51 (0.41-0.65) | - |
Li et al. [14] (2012) | Cases from a population-based case control study followed as a cohort | 1,024 | - | Mean 7.3 | - | 0.89 (0.52-1.52) | 0.82 (0.54-1.24) |
Beta-blockers | Â | Â | Â | Â | Â | Â | Â |
Powe et al. [21] (2010) | UK, stages I-III | 466 | 43 (9%) | Mean 10.3 | 0.43b (0.20-0.93) | 0.29 (0.12-0.71) | - |
Melhem-Bertrandt et al. [22] (2011) | MD Anderson triple-negative stages I-III | 1,413 | 102 (7%) | Median 4.6 | 0.52a (0.31-0.88) | - | 0.64 (0.38-1.07) |
Ganz et al. [23] (2011) | LACE cohort, stages I-IIIA, with linked pharmacy records | 1,779 | 270 (15%) | Mean 8.2 | 0.86a (0.57-1.32) | 0.76 (0.44-1.33) | 1.04 (0.72-1.51) |
Barron et al. [24] (2011) | Nested case control linked Irish cancer and pharmacy registries, stages I-IV | 5,333 | Propranolol = 70 | Median 3.5 | - | 0.19 (0.06-0.60) | -- |
 |  |  | Atenolol = 525 (matched 1:2) |  |  | 1.16 (0.84-1.61) | - |
Angiotensin-converting enzyme inhibitors (ACEIs) and angiontensin type I receptor blockers (ARBs) | |||||||
Melhem-Bertrandt et al. [22] (2011) | MD Anderson triple-negative stages I-III | 1,413 | 140 (10%)c | Median 4.6 | 0.82a (0.54-1.26) | - | 0.99 (0.65-1.51) |
Ganz et al. [23] (2011) | LACE cohort, stages I-IIIA, with linked pharmacy records | 1,779 | 137 (8%)d | Mean 8.2 | 1.56a (1.02-2.39) | 1.27 (0.74-2.19) | 1.23 (0.82-1.83) |
Chae et al. [30] (2011) | Stage II/III hospital patients | 703 | 168 (24%) | Median 4.6 | 0.49a (0.31-0.76) | - | NS |
Statins | |||||||
Kwan et al. [33] (2008) | LACE cohort, stages I-IIIA, with linked pharmacy records | 1,811 | 367 (20%) | Mean 5.0 | 0.67a (0.39-1.13) | - | - |
Ahern et al. [34] (2011) | Danish registry cohort with linked pharmacy records, stages I-III | 18,769 | 140 (10%)c | Median 6.8 | 0.83a (0.70-0.98) | - | - |
Chae et al. [30] (2011) | Stage II/III hospital patients | 703 | 156 (22%) | Median 4.6 | 0.40a (0.24-0.67) | - | NS |
Metformin | Â | Â | Â | Â | Â | Â | Â |
He et al. [42] (2012) | MD Anderson HER2-positive stages II-IV | 1,983 | 66 (3.3%) | Median 4.0 | - | 0.47 (0.24-0.90) | 0.52 (0.28-0.97) |
Bayraktar et al. [46] (2012) | MD Anderson, triple-negative on adjuvant chemotherapy, stages I-III | 1,448 | 63 (4.4%) meformin, 67 (4.6%) on other anti-diabetics | Median 5.2 | 1.63b (0.87-3.06) for diabetics not on metformin, compared with diabetics on metformin | Â | 1.22 (0.66-2.28) for diabetics not on metformin, compared with diabetics on metformin |
Currie et al. [44] (2012) | UK, patients with solid tumors, including breast cancer stages I-IV | 112,408 (25,575 breast cancer) | 1,428 (1.3%) metformin alone, 1,125 (1.0%) metformin + sulfonylurea 290 (0.3%) metformin + insulin | Mean 9.3, median 6.8 (overall survival) | - | - | 0.96e (0.64-1.43) |